Oxurion (ex ThromboGenics)

BRU: OXUR | BE0003846632
Euronext Brussel

Mijn selectie

2,560 EUR (-2,29%)

26 februari 2021

Kosten order 3.000 EUR: 2,90 EUR

Begin direct met beleggen bij DEGIRO* »

* Met beleggen kunt u uw inleg verliezen

Vandaag

2,580

2,650

12 maanden

2,140

3,310

Kosten order 3.000 EUR: 2,90 EUR
Begin direct met beleggen bij DEGIRO »

Laatste nieuws over Oxurion

Oxurion NV appoints Prof Alan Stitt as Chief Scientific Officer

20 januari 2021 - 08:00 | Oxurion NV

Leuven, BE and Boston, MA, US - January 20, 2021 – 08.00 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care ophthalmic therapies, with a focus on diabetic macular edema (DME), is pleased to announce the...
Trivano.com »

OXURION to Participate in Upcoming Investor Meetings

07 januari 2021 - 08:00 | Oxurion NV

OXURION to Participate in Upcoming Investor Meetings Leuven, BELGIUM, Boston, MA, US - January 7, 2021 – 08.00 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care ophthalmic therapies, with a focus on...
Trivano.com »

OXURION NV Confirms New Patents for THR-687 Issued by European and US Patent Offices

09 november 2020 - 07:30 | Oxurion NV

OXURION NV Confirms New Patents for THR-687 Issued by European and US Patent Offices Composition-of-matter patents protect THR-687 until 2039-2044 Leuven, Belgium and Boston, MA, November 9, 2020 – 7.30 AM CET – Oxurion NV (Euronext Brussels: OXUR), a...
Trivano.com »

ONCURIOUS I-O Portfolio Directed at Boosting T Cell Influx and Activity in Solid Tumors Announcing First Preclinical Proof of Concept in Proprietary CCR8 Treg Program

22 oktober 2020 - 18:47 | Oxurion NV

Strategic focus of immuno-oncology (I-O) portfolio on modulation of tumor microenvironment to enhance T cell influx and activity in immune excluded solid tumors, aspects that immune checkpoint inhibitors do not address.Preclinical Proof of Concept for Company’s priority...
Trivano.com »

Oxurion NV Business Update – Q3 2020

15 oktober 2020 - 08:00 | Oxurion NV

Oxurion NV Business Update – Q3 2020 Progressing Clinical Development of Next Generation Diabetic Macular Edema (DME) Therapies – Beyond anti-VEGF First Patient dosed in Phase 2 study (‘KALAHARI’) evaluating THR-149, a potent plasma kallikrein inhibitor, for the...
Trivano.com »

Oxurion NV appoints Tom Graney, CFA as Chief Financial Officer

13 oktober 2020 - 17:45 | Oxurion NV

Invitation OXURION R&D Investor Day – Virtual - 15 October 2020 at 5.30pm CET/ 11.30am ET

08 oktober 2020 - 08:00 | Oxurion NV

Invitation OXURION R&D Investor Day – Virtual - 15 October 2020 at 5.30pm CET/ 11.30am ET

08 oktober 2020 - 08:00 | Oxurion NV

Save The Date: Oxurion to host Virtual R&D Investor Day on 15 October 2020

05 oktober 2020 - 10:00 | Oxurion NV

Save The Date: Oxurion to host Virtual R&D Investor Day on 15 October 2020

05 oktober 2020 - 10:00 | Oxurion NV

Oxurion NV to Present New Pre-Clinical Data on THR-687 at EURETINA 2020 Virtual Meeting, Oct 2-4

29 september 2020 - 08:00 | Oxurion NV

Oxurion NV Business Update - H1 2020

17 september 2020 - 17:45 | Oxurion NV

Oxurion NV to Present at H.C. Wainwright & Co 22nd Annual Global Investment Conference

14 september 2020 - 08:00 | Oxurion NV

Oxurion NV to Present at H.C. Wainwright & Co 22nd Annual Global Investment Conference

14 september 2020 - 08:00 | Oxurion NV

Oxurion NV Business Update and First Half 2020 Financial Results to be announced on 17 September

11 september 2020 - 08:15 | Oxurion NV

Oudere nieuwsberichten »